Low-Density Lipoprotein Cholesterol and the On-Target Effects of Therapy: How Low Is Too Low?
Divisions of Cardiovascular and Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: beverett@partners.org.
Brendan M
BM
Everett
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D008078:Cholesterol, LDL; D000071449:Proprotein Convertase 9; D016032:Randomized Controlled Trials as Topic
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D008078:Cholesterol, LDL; D000071449:Proprotein Convertase 9; C571059:alirocumab
LDL cholesterol; PCSK9 inhibitors; adverse effects; lipids